The award is presented by PMWC and Prescience International. Recombinant was selected from among 31 entrants and was the only software company among the top three finalists which included biotech companies Auxogyn and Epizyme. Winners were selected by a panel of judges and attendee voting.
According to Tal Behar, co-founder of PMWC, the Competition showcases some of the world's most promising personalized medicine innovations. "Customization of treatment, with all decisions and practices being tailored to the individual, will be a revolution of the current healthcare cycle. We look forward to seeing how the companies highlighted during this year's Competition will define the next generation of personalized medicine," said Behar.
The PMWC 2012 Most Promising Company award is conferred to companies with technology, products or services that are disruptive and innovative to the current standard-of-care, both in cost and effectiveness; strength of team and ability to execute; barriers to competition and strength of intellectual property; and expected financial returns for investors.
"Being a finalist in the Most Promising Company Competition highlights Recombinant Data's success in providing critical data infrastructure and analytics solutions to leading pharma and biotech companies, academic medical centers and healthcare delivery systems," said Peter Emerson, CEO of Recombinant Data. "Linking data from patient care, clinical research and basic life science research and having the ability to analyze and interpret that data is essential to advancing personalized medicine. Recombinant Data is committed to this goal."
"We congratulate Recombinant Data and all of the companies competing this year," said Melinda Richter, founder and CEO, Prescience International. "The quality of entries demonstrates that personalized medicine will play an increasingly significant role in delivering high-quality, cost-effective healthcare and it will continue to grow in importance as scientific breakthroughs are translated into a new generation of targeted therapeutics."